Wedbush Maintains Outperform on SpringWorks Therapeutics, Lowers Price Target to $50
Wedbush analyst David Nierengarten maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Outperform and lowers the price target from $110 to $50.
SpringWorks Therapeutics To Present At ASCO Jun. 5
- Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -
- Long-Term Follow-up Data from
Why SpringWorks Shares Are Soaring Today Premarket
SpringWorks Therapeutics Inc (NASDAQ: SWTX) has announced positive topline results from the DeFi Phase 3 trial evaluating nirogacestat in adult patients with progressing desmoid tumors.
The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours:
SpringWorks Therapeutics Q1 EPS $(1.26) Down From $(0.62) YoY
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.26) per share. This is a 103.23 percent decrease over losses of $(0.62) per share from the same period last year.
